The S&P 500's Weird New Contenders Are Sending Conflicting Signals—Here's What Actually Matters

---

Wall Street’s current obsession with the S&P 500’s next batch of additions has all the clarity of a foggy trading floor at 7 a.m.—which is to say, none.

We’ve got ten stocks vying for inclusion as “New Contenders,” and the analyst community is essentially having a public argument about which ones belong. That’s not noise. That’s a signal that the market hasn’t priced in the real winners yet.

When Analysts Disagree, Someone’s Wrong (And Nobody Knows Who)

Start with the copper play. Wells Fargo just cut Southern Copper’s (SCCO) price target from $192 to $186 on April 15, citing a copper rally as the reason to go lower. Read that again. The commodity’s surging, so the analyst who covers the company best positioned to benefit is trimming her target by $6. She kept an Equal Weight rating, which in analyst-speak means “this thing’s boring me.”

Meanwhile, over in the AI/data center corner, Cantor Fitzgerald’s doing the opposite. They hiked Strategy Inc.’s (MSTR) target from $192 to $212 on April 21—a $20 pop—while acknowledging they’re worried about macro headwinds. That’s the kind of contradiction you see right before someone gets really right or really wrong. Not much middle ground.

Then JPMorgan took a $25 hammer to Everpure (P), dropping the price target from $105 to $80 on April 16. But—and this matters—they kept an Overweight rating. So JPM’s saying “yeah, I like this company long-term, but the current valuation’s disconnected from reality.” That’s the move of a house that’s either picking a genuine dip or quietly backing away from a hype trade.

My read: We’re watching three different analyst narratives collide. Copper’s having a moment, but the Street’s skeptical about sustained demand. AI’s the hot story, but macro risks are making even the bulls queasy. And Everpure’s caught in that classic biotech/growth trap where the fundamentals don’t match the price.

Photo by Shamia Casiano / Pexels

The Real Action Is Somewhere Else Entirely

Here’s where it gets interesting. While these ten contenders are fighting over analyst target sheets, other market movers are actually doing things.

SoFi Technologies (SOFI) launched a fully digital HELOC on April 22. That’s not sexy. Nobody tweets about home equity lines of credit. But it’s the move of a company that’s figured out how to compete in fintech without relying on hype cycles or rate tailwinds. They’re eating Wells Fargo’s lunch in a product category that’s been boring and profitable for decades. If SoFi can digitize home lending the way they’ve digitized student loan refinancing, this matters way more than whatever’s happening with their stock price this month.

Alnylam Pharmaceuticals (ALNY) advanced an RNAi diabetes drug into Phase 2 trials on April 17. Type 2 diabetes is the most profitable disease in modern medicine—GLP-1 agonists made Novo Nordisk one of the world’s most valuable companies. An RNAi play in that space isn’t a lottery ticket; it’s a direct shot at one of the biggest addressable markets on Earth. Whether the Street prices that in is almost irrelevant to whether it works.

These two plays—digital financial infrastructure and next-gen therapeutics—are where the real money is being made. Not in watching Wells Fargo adjust copper targets.

Photo by Markus Spiske / Pexels

The Geopolitical Tax Nobody’s Pricing In Yet

Then there’s the background radiation that’s been steadily intensifying.

Iran’s making peace proposals to the U.S. on the Hormuz Strait situation. European markets opened higher on that news. That sounds great until you remember that “peace proposal” talks have been stalling for months, and every time they flare up, oil markets twitch. China’s industrial profits jumped 15.8% in March fueled by AI and chip demand—solid—but they explicitly noted that rising global oil prices are “seeping into the domestic economy” and squeezing manufacturers’ margins.

Translation: the world’s largest manufacturing hub is starting to feel the squeeze from energy costs. Oil doesn’t need to spike dramatically to matter. It just needs to stay elevated enough to slowly erode margins across every downstream sector.

Business leaders are spooked. We know this because actual conversations with thirty-plus CEOs show war, inflation, and AI are now the baseline operating assumption. Not outliers. Baseline. That’s the kind of comment that usually precedes a 5-8% market correction, not because the fundamental thesis changes, but because consensus always gets too comfortable right before it doesn’t.

My prediction: We hit mid-May without a meaningful move in the broader market, then some combination of oil news, inflation data, or Iran developments forces a reassessment. The S&P 500’s valuation isn’t absurd, but it’s pricing in a lot of “good news continues.” It’s not pricing in “good news pauses.”

The Uncomfortable Truth About These Ten Contenders

Here’s what actually matters about SCCO, MSTR, P, SOFI, and ALNY all being on the same “New Contenders” list: they’re not actually in the same market.

SCCO’s a commodity play masquerading as an industrial stock. MSTR’s whatever the current consensus thinks AI money is. P’s a biotech growth story fighting valuation gravity. SOFI’s a fintech incumbent-killer. ALNY’s a shot at the next trillion-dollar drug category.

The only thing binding them together is index size and recent analyst enthusiasm. That’s not a portfolio. That’s a trading desk’s Friday-afternoon lunch conversation turned into an investment thesis.

If I’m being honest—and I should be—I don’t know which of these ten actually deserves to be in the S&P 500. What I do know is that the ones making actual moves (SoFi’s digital HELOC, Alnylam’s Phase 2 advancement) are more interesting than the ones getting analyst target shuffles. Because moves suggest management has figured out something about their business. Target adjustments suggest the analyst community’s still figuring out what the business is.

What I’m Watching

• Oil price and Hormuz news through May 10: If geopolitical tensions ease, energy costs stabilize, and margins across manufacturing remain resilient, the broader market keeps climbing. If talks stall and crude stays above $82/barrel, expect a 3-5% pullback by late May driven by margin anxiety.

• SoFi’s HELOC adoption metrics by end of Q2: The digital lending play only matters if actual customers use it. Watch for guidance updates mentioning HELOC volume. If they’re getting real traction, this is a $35-40 stock in 18 months. If adoption’s tepid, it’s a $22 stock.

• Alnylam’s Phase 2 diabetes trial readout timeline: RNAi therapeutics are either breakthrough or dead-on-arrival with no middle ground. The next 12-18 months will determine whether ALN-4324 actually works. Any positive interim data and this doubles. Any safety signal and it gets cut in half.

• S&P 500 valuation vs. oil prices mid-May: If we get simultaneous evidence of slowing growth + sticky inflation + geopolitical risk without a corresponding earnings upgrade, the market reprices. Watch for the 10-year yield to spike above 4.4% on inflation concern. That’s your tell.